Socioeconomic Costs and Health Inequalities from Psoriasis: A Cohort Study

Dermatology ◽  
2019 ◽  
Vol 235 (5) ◽  
pp. 372-379 ◽  
Author(s):  
Simon Francis Thomsen ◽  
Lone Skov ◽  
Rikke Dodge ◽  
Morten Storling Hedegaard ◽  
Jakob Kjellberg
Keyword(s):  
Health Care ◽  
Health Care Costs ◽  
Odds Ratio ◽  
Care Management ◽  
Health Care Management ◽  
Indirect Costs ◽  
National Patient ◽  
Matched Study ◽  
The Impact ◽  
Care Costs

Background: To date, there are no nationwide studies of the social and economic burden of psoriasis to patients in Denmark. Incentives for health care management based on patient-related outcomes and value (IMPROVE) in psoriasis and psoriatic arthritis is a project aimed at assisting movement from activity-based to outcome-based health care management. One of the key objectives in IMPROVE is to describe the disease-associated socioeconomic burden of psoriasis. Methods: A case-matched study of the impact of psoriasis on patients’ income, employment and health care costs in Denmark was performed. The IMPROVE study was a retrospective analysis of patients with a hospital diagnosis of psoriasis identified from the Danish National Patient Registry (NPR). In total, 13,025 psoriasis patients and 25,629 matched controls were identified from the NPR. Data from psoriasis patients and matched controls were compared for social and economic factors including income, employment, health care costs and risk of comorbidities. Results: Psoriasis was associated with increased health care costs (mean annual costs +116% compared to control, p < 0.001), peaking in the year of referral to hospital for psoriasis and sustained thereafter. Both direct and indirect costs were significantly higher for patients with psoriasis than controls (p < 0.001). In the years before and immediately following hospital diagnosis, the rates of employment were lower in psoriasis patients than controls. Comorbidities, including cardiovascular (odds ratio 1.93 [95% CI 1.77–2.09]) and psychiatric conditions (odds ratio 2.61 [95% CI 2.30–2.97]), were more prevalent in patients with psoriasis than controls. Conclusion: In Denmark, psoriasis has a significant impact on health care costs, income and employment, and is associated with a range of comorbidities.

Economic and Social Burden of Multiple Myeloma in Italy: The Co.Mi.M. Study

Blood ◽  
2008 ◽  
Vol 112 (11) ◽  
pp. 2393-2393
Author(s):  
Maria Teresa Petrucci ◽  
Elisabetta Calabrese ◽  
Anna Levi ◽  
Vincenzo Federico ◽  
Michela Ceccolini ◽  
...  
Keyword(s):  
Health Care ◽  
Multiple Myeloma ◽  
Clinical Outcomes ◽  
Resource Utilization ◽  
Health Care Costs ◽  
Indirect Costs ◽  
Sample Distribution ◽  
Clinical Records ◽  
The Impact ◽  
Care Costs

Abstract Background. Few data are available on the impact of multiple myeloma (MM) on Italian healthcare expenditure and society broadly. This is especially important because of the increased prevalence of MM in Italy. Aim and methods. The Co.Mi.M. study is a cross-sectional retrospective, prevalence-based study (Tarricone, Health Policy, 2006) that involved 5 Italian hematologic institutions and designed to measure resource utilization associated with MM management in terms of direct and indirect costs in a societal perspective. A specific questionnaire was administered to obtain anonymous, subject-level data on health-care utilization and costs in 236 subjects with MM. Quality of Life (QoL) data collection was included in the protocol. Data sources included clinical records and interviews with physicians and patients. Four disease-phases were considered in a stratified distribution that reflects real clinical practice: asymptomatic (“watch and wait”); symptomatic, receiving an autotransplant; symptomatic, receiving drugs; and plateau/remission. Costs were identified over 1 year of disease management with regard to: drugs; visits; laboratory tests; hospital admissions; support devices; home assistance; travel; and reduced productivity of patients and caregivers. Costs for lost working days were derived according to the human capital method using national average earnings per working category. No clinical outcomes were collected. Health-related QoL was measured using the EORTC QLQ-C30. Results. The sample distribution was as follows: 16.5% asymptomatic; 12.3% symptomatic, receiving an autotransplant; 44.5% symptomatic, receiving drugs; and 26.7% plateau/remission. The average social costs per subject per year were €20,868. Direct health-care costs (hospitalizations, drugs, diagnostics, visits, etc) were €16,867 per subject per year; direct non-health care costs (transportation, hotels, paid care, etc.) were €1,776 per patient per year; indirect costs (productivity loss) were €2,225 per subject per year. The average direct health care costs per subject per year in the different subgroups were: €755, €53,102; €18,882; €6,803. The groups with the highest resource utilization were (b) the autotransplanted and (c) those receiving drugs. Specifically, 95% of total hospitalizations were related to autotransplant. Conclusion. The main resource utilization comes for direct medical costs. MM treatment strategy has changed dramatically in the last years. In particular, transplant and pharmacological treatments represent the most relevant costs, although counterbalanced by the highly increased clinical outcomes reported in the literature. After year 2000 the post-relapse survival has steadily improved. In particular, an improvement in survival amongst patients who had access to one or more innovative drugs has been demonstrated (Shaji Kumar, Blood, 2007).

The Impact of Physical Activity on Mitigation of Health Care Costs Related to Diabetes Mellitus: Findings from Developed and Developing Settings

2016 ◽  
Vol 12 (4) ◽  
pp. 307-311 ◽  
Author(s):  
Bruna Camilo Turi ◽  
Henrique Luiz Monteiro ◽  
Rômulo Araújo Fernandes ◽  
Jamile Sanches Codogno
Keyword(s):  
Physical Activity ◽  
Diabetes Mellitus ◽  
Health Care ◽  
Health Care Costs ◽  
The Impact ◽  
Care Costs ◽  
Developing Settings

scholarly journals Trends in incidence rate, health care use, and costs due to rib fractures in the Netherlands

2021 ◽  
Author(s):  
Jonne T. H. Prins ◽  
Mathieu M. E. Wijffels ◽  
Sophie M. Wooldrik ◽  
Martien J. M. Panneman ◽  
Michael H. J. Verhofstad ◽  
...  
Keyword(s):  
Health Care ◽  
Incidence Rate ◽  
Health Care Costs ◽  
Indirect Costs ◽  
Rib Fractures ◽  
Work Absence ◽  
Lost Productivity ◽  
The Mean ◽  
Using Data ◽  
Care Costs

Abstract Purpose This study aimed to examine population-based trends in the incidence rate, health care consumption, and work absence with associated costs in patients with rib fractures. Methods A retrospective nationwide epidemiologic study was performed with data from patients with one or more rib fractures presented or admitted to a hospital in the Netherlands between January 1, 2015 and December 31, 2018 and have been registered in the Dutch Injury Surveillance System (DISS) or the Hospital Discharge Registry (HDR). Incidence rates were calculated using data from Statistics Netherlands. The associated direct health care costs, costs for lost productivity, and years lived with disability (YLD) were calculated using data from a questionnaire. Results In the 4-year study period, a total of 32,124 patients were registered of which 19,885 (61.9%) required hospitalization with a mean duration of 7.7 days. The incidence rate for the total cohort was 47.1 per 100,000 person years and increased with age. The mean associated direct health care costs were €6785 per patient and showed a sharp increase after the age of 75 years. The mean duration of work absence was 44.2 days with associated mean indirect costs for lost productivity of €22,886 per patient. The mean YLD was 0.35 years and decreased with age. Conclusion Rib fractures are common and associated with lengthy HLOS and work absenteeism as well as high direct and indirect costs which appear to be similar between patients with one or multiple rib fractures and mostly affected by admitted patients and age.

scholarly journals THU0548 THE ECONOMIC BURDEN OF ANKYLOSING SPONDYLITIS IN SPAIN. RESULTS OF THE SPANISH ATLAS 2017

2020 ◽  
Vol 79 (Suppl 1) ◽  
pp. 514.2-514
Author(s):  
M. Merino ◽  
O. Braçe ◽  
A. González ◽  
Á. Hidalgo-Vega ◽  
M. Garrido-Cumbrera ◽  
...  
Keyword(s):  
Health Care ◽  
Ankylosing Spondylitis ◽  
Health Care Costs ◽  
Health Care Cost ◽  
Labour Productivity ◽  
General Health Questionnaire ◽  
Indirect Costs ◽  
Productivity Losses ◽  
The Cost ◽  
Care Costs

Background:Ankylosing Spondylitis (AS) is a disease associated with a high number of comorbidities, chronic pain, functional disability, and resource consumption.Objectives:This study aimed to estimate the burden of disease for patients diagnosed with AS in Spain.Methods:Data from 578 unselected patients with AS were collected in 2016 for the Spanish Atlas of Axial Spondyloarthritis via an online survey. The estimated costs were: Direct Health Care Costs (borne by the National Health System, NHS) and Direct Non-Health Care Costs (borne by patients) were estimated with the bottom-up method, multiplying the resource consumption by the unit price of each resource. Indirect Costs (labour productivity losses) were estimated using the human capital method. Costs were compared between levels of disease activity using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) score (<4 or low inflammation versus ≥4 or high inflammation) and risk of mental distress using the 12-item General Health Questionnaire (GHQ-12) score (<3 or low risk versus ≥3 or high risk).Results:The average annual cost per patient with AS in 2015 amounted to €11,462.3 (± 13,745.5) per patient. Direct Health Care Cost meant an annual average of €6,999.8 (± 9,216.8) per patient, to which an annual average of €611.3 (± 1,276.5) per patient associated with Direct Non-Health Care Cost borne by patients must be added. Pharmacological treatment accounted for the largest percentage of the costs borne by the NHS (64.6%), while for patients most of the cost was attributed to rehabilitative therapies and/or physical activity (91%). The average annual Indirect Costs derived from labour productivity losses were €3,851.2 (± 8,484.0) per patient, mainly associated to absenteeism. All categories showed statistically significant differences (p<0.05) between BASDAI groups (<4 vs ≥4) except for the Direct Non-Healthcare Cost, showing a progressive rise in cost from low to high inflammation. Regarding the 12-item General Health Questionnaire (GHQ-12), all categories showed statistically significant differences between GHQ-12 (<3 vs ≥3), with higher costs associated with higher risk of poor mental health (Table 1).Table 1.Average annual costs per patient according to BASDAI and GHQ-12 groups (in Euros, 2015)NDirect Health CostsDirect Non-Health CostsIndirect CostsTotal CostBASDAI<4917,592.0*557.32,426.5*10,575.8*≥43769,706.9*768.05,104.8*15,579.7*Psychological distress (GHQ-12)<31468,146.8*493.6*3,927.2*12,567.6*≥32609,772.9*807.2*4,512.3*15,092.5*Total5786,999.8611.33,851.211,462.3* p <0.05Conclusion:Direct Health Care Costs, and those attributed to pharmacological treatment in particular, accounted for the largest component of the cost associated with AS. However, a significant proportion of the overall costs can be further attributed to labour productivity losses.Acknowledgments:Funded by Novartis Farmacéutica S.A.Disclosure of Interests:María Merino: None declared, Olta Braçe: None declared, Almudena González: None declared, Álvaro Hidalgo-Vega: None declared, Marco Garrido-Cumbrera: None declared, Jordi Gratacos-Masmitja Grant/research support from: a grant from Pfizzer to study implementation of multidisciplinary units to manage PSA in SPAIN, Consultant of: Pfizzer, MSD, ABBVIE, Janssen, Amgen, BMS, Novartis, Lilly, Speakers bureau: Pfizzer, MSD, ABBVIE, Janssen, Amgen, BMS, Novartis, Lilly

scholarly journals Direct access physiotherapy for patients with musculoskeletal disorders: a systematic review

2019 ◽  
Vol 29 (Supplement_4) ◽  
Author(s):  
A Demont ◽  
A Bourmaud ◽  
A Kechichian ◽  
F Desmeules
Keyword(s):  
Systematic Review ◽  
Health Care ◽  
Adverse Events ◽  
Usual Care ◽  
Musculoskeletal Disorders ◽  
Health Care Costs ◽  
Family Physician ◽  
Direct Access ◽  
The Impact ◽  
Care Costs

Abstract Background Although the benefits of physiotherapy is well supported in the literature, the impact of having direct access to physiotherapy is not well established. Update of the current available evidence is warranted. The aim of this systematic review was to update the current evidence regarding the impact of direct access physiotherapy compared to usual care for patients with musculoskeletal disorders. Methods Systematic searches were conducted in 5 bibliographic databases up until May 2018. Two independent raters reviewed studies and used the Quality Assessment Tool for Quantitative Studies to conduct the methodological quality assessment and a data extraction regarding patient outcomes, adverse events, health care utilization and processes, patient satisfaction and health care costs. Results Sixteen studies of weak to moderate quality were included. Five studies found no significant differences in pain reduction between usual family physician led care and direct access physiotherapy. However, three studies reported better clinical outcomes in patients with direct access in terms of function and quality of life. Five studies did not observe any adverse events with direct access physiotherapy. Three studies showed shorter waiting time and four studies reported fewer number of physiotherapy visits with direct access. Three studies showed that patients with direct access were less likely to have medication and imaging tests prescribed compared to usual care. Five studies reported higher levels of satisfaction for direct access. In terms of health care costs, four studies demonstrated that costs were lower with direct access and one study reported similar costs between both types of care. Conclusions Emerging evidence, although of weak to moderate quality, suggest that direct access physiotherapy provides equal or better outcomes than family physician led care models for musculoskeletal disorders patients. More methodologically strong studies are needed. Key messages This review supports the efficacy, safety and cost-effectiveness of direct access PT, while increasing access to care with a more efficient use of resources. There is a need for more methodologically strong studies to evaluate the efficiency of direct access models of care of physiotherapy for patients with MSKD.

scholarly journals PSK6 THE IMPACT OF PSORIASIS ON HEALTH CARE COSTS AND WORK LOSS

2007 ◽  
Vol 10 (3) ◽  
pp. A100-A101
Author(s):  
MS Duh ◽  
JF Fowler ◽  
L Rovba ◽  
S Buteau ◽  
L Pinheiro ◽  
...  
Keyword(s):  
Health Care ◽  
Health Care Costs ◽  
Work Loss ◽  
The Impact ◽  
Care Costs

The Impact of Weight Reduction Surgery on Health-Care Costs in Morbidly Obese Patients

2004 ◽  
Vol 14 (7) ◽  
pp. 939-947 ◽  
Author(s):  
John S. Sampalis ◽  
Moishe Liberman ◽  
Stephane Auger ◽  
Nicolas V. Christou
Keyword(s):  
Health Care ◽  
Health Care Costs ◽  
Weight Reduction ◽  
Morbidly Obese ◽  
Obese Patients ◽  
The Impact ◽  
Care Costs
Sign in / Sign up

Export Citation Format

Share Document